Life Sciences

Pfizer to settle Bextra, Celebrex claims for $894M

Pharma Compliance Alert, October 22, 2008

Pfizer has agreed in principle to pay $894 million to settle all lawsuits related to its non-steroidal anti-inflammatory drugs Bextra and Celebrex, according to a company release.

The settlement covers more than 90% of the personal injury lawsuits filed by patients who claim the drugs caused a heart attack, stroke, or other injury. The settlement also resolves payer class action consumer fraud cases involving Bextra and Celebrex in which plaintiffs allege economic loss relating to the promotion of these medications.

Pfizer also reached an agreement to settle claims by 33 states and the District of Columbia relating to alleged marketing practices for Bextra.

Comments

0 comments on “Pfizer to settle Bextra, Celebrex claims for $894M

 

Most Popular

Related Articles